1
|
Koziolek M, Augustijns P, Berger C, Cristofoletti R, Dahlgren D, Keemink J, Matsson P, McCartney F, Metzger M, Mezler M, Niessen J, Polli JE, Vertzoni M, Weitschies W, Dressman J. Challenges in Permeability Assessment for Oral Drug Product Development. Pharmaceutics 2023; 15:2397. [PMID: 37896157 PMCID: PMC10609725 DOI: 10.3390/pharmaceutics15102397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Revised: 09/12/2023] [Accepted: 09/19/2023] [Indexed: 10/29/2023] Open
Abstract
Drug permeation across the intestinal epithelium is a prerequisite for successful oral drug delivery. The increased interest in oral administration of peptides, as well as poorly soluble and poorly permeable compounds such as drugs for targeted protein degradation, have made permeability a key parameter in oral drug product development. This review describes the various in vitro, in silico and in vivo methodologies that are applied to determine drug permeability in the human gastrointestinal tract and identifies how they are applied in the different stages of drug development. The various methods used to predict, estimate or measure permeability values, ranging from in silico and in vitro methods all the way to studies in animals and humans, are discussed with regard to their advantages, limitations and applications. A special focus is put on novel techniques such as computational approaches, gut-on-chip models and human tissue-based models, where significant progress has been made in the last few years. In addition, the impact of permeability estimations on PK predictions in PBPK modeling, the degree to which excipients can affect drug permeability in clinical studies and the requirements for colonic drug absorption are addressed.
Collapse
Affiliation(s)
- Mirko Koziolek
- NCE Drug Product Development, Development Sciences, AbbVie Deutschland GmbH & Co. KG, 67061 Ludwigshafen, Germany
| | - Patrick Augustijns
- Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium
| | - Constantin Berger
- Chair of Tissue Engineering and Regenerative Medicine, University Hospital Würzburg, 97070 Würzburg, Germany;
| | - Rodrigo Cristofoletti
- Department of Pharmaceutics, University of Florida, 6550 Sanger Road, Orlando, FL 32827, USA
| | - David Dahlgren
- Department of Pharmaceutical Biosciences, Uppsala University, 75124 Uppsala, Sweden (J.N.)
| | - Janneke Keemink
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, 4070 Basel, Switzerland;
| | - Pär Matsson
- Department of Pharmacology and SciLifeLab Gothenburg, University of Gothenburg, 40530 Gothenburg, Sweden;
| | - Fiona McCartney
- School of Veterinary Medicine, University College Dublin, D04 V1W8 Dublin, Ireland;
| | - Marco Metzger
- Translational Center for Regenerative Therapies (TLZ-RT) Würzburg, Branch of the Fraunhofer Institute for Silicate Research (ISC), 97082 Würzburg, Germany
| | - Mario Mezler
- Quantitative, Translational & ADME Sciences, AbbVie Deutschland GmbH & Co. KG, 67061 Ludwigshafen, Germany;
| | - Janis Niessen
- Department of Pharmaceutical Biosciences, Uppsala University, 75124 Uppsala, Sweden (J.N.)
| | - James E. Polli
- Department of Pharmaceutical Sciences, University of Maryland, Baltimore, MD 21021, USA;
| | - Maria Vertzoni
- Department of Pharmacy, National and Kapodistrian University of Athens, 157 84 Zografou, Greece;
| | - Werner Weitschies
- Institute of Pharmacy, University of Greifswald, 17489 Greifswald, Germany
| | - Jennifer Dressman
- Fraunhofer Institute of Translational Medicine and Pharmacology, 60596 Frankfurt, Germany
| |
Collapse
|
2
|
Fu T, Gao R, Scott-Stevens P, Chen Y, Zhang C, Wang J, Summerfield S, Liu H, Sahi J. Rapid Bioavailability and Disposition protocol: A novel higher throughput approach to assess pharmacokinetics and steady-state brain distribution with reduced animal usage. Eur J Pharm Sci 2018; 122:13-21. [PMID: 29857045 DOI: 10.1016/j.ejps.2018.05.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Revised: 05/28/2018] [Accepted: 05/28/2018] [Indexed: 11/18/2022]
Abstract
Besides routine pharmacokinetic (PK) parameters, unbound brain-to-blood concentration ratio (Kp,uu) is an index particularly crucial in drug discovery for central nervous system (CNS) indications. Despite advantages of Kp,uu from steady state after constant intravenous (i.v.) infusion compared with one- or multiple time points after transient dosing, it is seldom obtained for compound optimization in early phase of CNS drug discovery due to requirement of prerequisite PK data to inform the study design. Here, we designed a novel rat in vivo PK protocol, dubbed as Rapid Bioavailability and Disposition (RBD), which combined oral (p.o.) dosing and i.v. infusion to obtain steady-state brain penetration, along with blood clearance, oral exposure and oral bioavailability for each discovery compound, within a 24 hour in-life experiment and only a few (e.g., 3) animals. Protocol validity was verified through simulations with a range of PK parameters in compartmental models as well as data comparison for nine compounds with distinct PK profiles. PK parameters (Kp,brain, CLb and oral AUC) measured from the RBD protocol for all compounds, were within two-fold and/or statistically similar to those derived from conventional i.v./p.o. crossover PK studies. Our data clearly indicates that the RBD protocol offers reliable and reproducible data over a wide range of PK properties, with reduced turnaround time and animal usage.
Collapse
Affiliation(s)
- Tingting Fu
- Platform Technology and Science, GlaxoSmithKline R&D Shanghai, China.
| | - Ruina Gao
- Platform Technology and Science, GlaxoSmithKline R&D Shanghai, China
| | | | - Yan Chen
- Platform Technology and Science, GlaxoSmithKline R&D Shanghai, China
| | - Chalmers Zhang
- Platform Technology and Science, GlaxoSmithKline R&D Shanghai, China
| | - Jianfei Wang
- Platform Technology and Science, GlaxoSmithKline R&D Shanghai, China
| | | | - Houfu Liu
- Platform Technology and Science, GlaxoSmithKline R&D Shanghai, China
| | - Jasminder Sahi
- Platform Technology and Science, GlaxoSmithKline R&D Shanghai, China
| |
Collapse
|
3
|
Hu J, Li G, Huang ZB, Zhang J, Shi DQ, Zhao Y. Pd-Catalyzed thiophene directed regioselective functionalization of arenes: a direct approach to multiply-substituted benzyl amines. Org Chem Front 2017. [DOI: 10.1039/c7qo00236j] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
A thiophene directed ortho-C–H functionalization via a palladium catalyst in the synthesis of multiply-substituted benzyl amines has been developed.
Collapse
Affiliation(s)
- Jundie Hu
- Key Laboratory of Organic Synthesis of Jiangsu Province
- College of Chemistry
- Chemical Engineering and Materials Science Soochow University
- Suzhou 215123
- China
| | - Guobao Li
- Key Laboratory of Organic Synthesis of Jiangsu Province
- College of Chemistry
- Chemical Engineering and Materials Science Soochow University
- Suzhou 215123
- China
| | - Zhi-Bin Huang
- Key Laboratory of Organic Synthesis of Jiangsu Province
- College of Chemistry
- Chemical Engineering and Materials Science Soochow University
- Suzhou 215123
- China
| | - Jingyu Zhang
- College of Physics
- Optoelectronics and Energy & Collaborative Innovation Center of Suzhou Nano Science and Technology
- Soochow University
- Suzhou 215006
- China
| | - Da-Qing Shi
- Key Laboratory of Organic Synthesis of Jiangsu Province
- College of Chemistry
- Chemical Engineering and Materials Science Soochow University
- Suzhou 215123
- China
| | - Yingsheng Zhao
- Key Laboratory of Organic Synthesis of Jiangsu Province
- College of Chemistry
- Chemical Engineering and Materials Science Soochow University
- Suzhou 215123
- China
| |
Collapse
|
4
|
Zhang X, Lv H, Zhou Q, Elkholi R, Chipuk JE, Reddy MVR, Reddy EP, Gallo JM. Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models. Mol Cancer Ther 2014; 13:1105-16. [PMID: 24568969 DOI: 10.1158/1535-7163.mct-13-0847] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
ON123300 is a low molecular weight multikinase inhibitor identified through a series of screens that supported further analyses for brain tumor chemotherapy. Biochemical assays indicated that ON123300 was a strong inhibitor of Ark5 and CDK4, as well as growth factor receptor tyrosine kinases such as β-type platelet-derived growth factor receptor (PDGFRβ). ON123300 inhibited U87 glioma cell proliferation with an IC(50) 3.4 ± 0.1 μmol/L and reduced phosphorylation of Akt, yet it also unexpectedly induced Erk activation, both in a dose- and time-dependent manner that subsequently was attributed to relieving Akt-mediated C-Raf S259 inactivation and activating a p70S6K-initiated PI3K-negative feedback loop. Cotreatment with the EGFR inhibitor gefitinib produced synergistic cytotoxic effects. Pursuant to the in vitro studies, in vivo pharmacokinetic and pharmacodynamic studies of ON123300 were completed in mice bearing intracerebral U87 tumors following intravenous doses of 5 and 25 mg/kg alone, and also at the higher dose concurrently with gefitinib. ON123300 showed high brain and brain tumor accumulation based on brain partition coefficient values of at least 2.5. Consistent with the in vitro studies, single agent ON123300 caused a dose-dependent suppression of phosphorylation of Akt as well as activation of Erk in brain tumors, whereas addition of gefitinib to the ON123300 regimen significantly enhanced p-Akt inhibition and prevented Erk activation. In summary, ON123300 demonstrated favorable pharmacokinetic characteristics, and future development for brain tumor therapy would require use of combinations, such as gefitinib, that mitigate its Erk activation and enhance its activity.
Collapse
Affiliation(s)
- Xiaoping Zhang
- Authors' Affiliations: Departments of Pharmacology and Systems Therapeutics and Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York; and Department of Pharmaceutical Science, University of South Florida, Tampa, Florida
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Awasthi A, Lohani M, Singh MK, Singh AT, Jaggi M. Pharmacokinetic evaluation of C-3 modified 1,8-naphthyridine-3-carboxamide derivatives with potent anticancer activity: lead finding. J Enzyme Inhib Med Chem 2013; 29:710-21. [PMID: 24156741 DOI: 10.3109/14756366.2013.845817] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
To develop naphthyridine derivatives as anticancer candidates, pharmacokinetic (PK) evaluations of 10 novel derivatives of 1,4-dihydro-4-oxo-1-proparagyl-1,8-naphthyridine-3-carboxamide, with potent anticancer activity were done using in vitro ADME (absorption, distribution, metabolism, excretion) and pharmacokinetic--pharmcodynamic (PK/PD) assays. Only derivatives 5, 6, 9 and 10 showed better metabolic stability, solubility, permeability, partition coefficient and cytochrome P450 (CYP) inhibition values. PK of derivatives 5, 6, 9 and 10 in rat showed comparable PK profile for derivative 5 (C0 = 6.98 µg/mL) and 6 (C0 = 6.61 µg/mL) with no detectable plasma levels for derivatives 9 and 10 at 5.0 mg/kg i.v. dose. PK/PD assay of derivatives 5 and 6 in tumor-bearing mice (TBM) showed comparable PK but tumor plasma index (TPI) of derivative 6 (4.02) was better than derivative 5 (2.50), suggesting better tumor uptake of derivative 6. Derivative 6, as lead compound, showed highest tumor growth inhibition (TGI) value of 33.6% in human ovary cancer xenograft model.
Collapse
Affiliation(s)
- Anshumali Awasthi
- Department of Drug Metabolism and Pharmacokinetics (DMPK), Dabur Research Foundation, Ghaziabad , Uttar Pradesh , India and
| | | | | | | | | |
Collapse
|
6
|
Ignatovich L, Muravenko V, Spura J, Popelis J, Domrachova I, Shestakova I. Synthesis, structure and cytotoxicity of new 2-[(3-aminopropyl)dimethylsilyl]-5-furfural diethylacetals and 2-[(3-aminopropyl)dimethylsilyl]-5-phenylfurans. Appl Organomet Chem 2013. [DOI: 10.1002/aoc.2995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
| | | | - Jana Spura
- Latvian Institute of Organic Synthesis; Riga LV 1006 Latvia
| | - Jury Popelis
- Latvian Institute of Organic Synthesis; Riga LV 1006 Latvia
| | | | | |
Collapse
|